CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY BENEFITS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PATENT ANALYSIS

3.3.1. Patent analysis by year
3.3.2. Patent analysis by region
3.3.3. Patent analysis by sleep disorder

3.4. GOVERNMENT REGULATIONS

3.4.1. U.S. FDA
3.4.2. Europe CE Mark
3.4.3. Ministry of Health, Labor, and Welfare (MHLW)

3.5. TOP PLAYERS POSITIONING, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Modern lifestyle increases the risk of sleep disorders
3.6.1.2. Stressful Work Condition and Working in Shifts
3.6.1.3. Rise in geriatric and obese population

3.6.2. Restraints

3.6.2.1. Adverse effects of sleep aid medication
3.6.2.2. Patent expiration

3.6.3. Opportunities

3.6.3.1. Technological Advancements Leading to Better Adoption
3.6.3.2. Untapped Markets in Developing Economies

CHAPTER 4 GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MATTRESSES AND PILLOWS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. SLEEP LABORATORIES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. MEDICATIONS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Prescription-based drugs
4.4.5. OTC drugs

4.5. SLEEP APNEA DEVICES

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5 SLEEP AIDS MARKET, BY SLEEP DISORDER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INSOMNIA

5.2.1. Market size and forecast

5.3. SLEEP APNEA

5.3.1. Market size and forecast

5.4. RESTLESS LEGS SYNDROME

5.4.1. Market size and forecast

5.5. NARCOLEPSY

5.5.1. Market size and forecast

5.6. SLEEPWALKING

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6 SLEEP AIDS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. CADWELL INDUSTRIES INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. COMPUMEDICS LIMITED

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. DRIVE DEVILBISS HEALTHCARE

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. GLAXOSMITHKLINE PLC

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. MERCK & CO., INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. NATUS MEDICAL INCORPORATED

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6.6. Key strategic moves and developments

7.7. PFIZER INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. KONINKLIJKE PHILIPS N.V.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. SANOFI

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. SLEEPMED INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments